[Neoadjuvant therapy of breast cancer using Newcastle disease virus].
The role of Newcastle disease virus and neoadjuvant therapy was assessed in 84 cases of breast cancer T1-4N0-2M0 (2005-2008). Combined use of the virus vaccine and chemotherapy (group A), therapy with the vaccine alone (group B) and chemotherapy regimen identical with that used in group A (group C) were compared. Histological pattern of tumor and stage were identified using expression of receptors of steroid hormones, oncoproteins Her2/neu and p53 as well as proliferation activity (marker Ki-67) before and after therapy. It was shown that the efficiency and safety of Newcastle disease virus (apathogenic strain La-Sotha) met specific immuno- and neoadjuvant therapy standards.
Keshelava
V V
VV
Dobrovol'skaia
N Iu
NIu
Chazova
N L
NL
Bershchanskaia
A M
AM
Podol'skaia
M V
MV
Garmarnik
T V
TV
Mel'nikova
N V
NV
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D019394:Ki-67 Antigen / Q000097:blood; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D009367:Neoplasm Staging; D009522:Newcastle disease virus; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000097:blood; D011960:Receptors, Estrogen / Q000097:blood; D011980:Receptors, Progesterone / Q000097:blood; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000097:blood
D014408:Biomarkers, Tumor; D019496:Cancer Vaccines; D019394:Ki-67 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D016159:Tumor Suppressor Protein p53; C508053:ERBB2 protein, human